Ocugen Inc

NASDAQ:OCGNUnited States

Ocugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. Its technology pipeline includes modifier gene therapy platform, regenerative medicine cell therapy platform, and biologic therapies for retinal diseases. The Company is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal disease (IRDs), including retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), Stargardt disease and multifactorial diseases such as dry age-related macular degeneration (dAMD) and geographic atrophy (GA). It is developing an inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine.

Contact Information

Headquarters

11 GREAT VALLEY PARKWAYMALVERN, PA, United States 19355

Phone

484-328-4701

Fax

302-655-5049

Executives

Chairman of the Board, Chief Executive Officer, Interim Principal Financial Officer

Shankar Musunuri

Controller

Michael Breininger

Chief Scientific Officer, Executive Officer, Head of Research and Development

Arun Upadhyay

Chief Medical Officer

Huma Qamar

Independent Director

Kirsten Castillo